<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56930">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364947</url>
  </required_header>
  <id_info>
    <org_study_id>339-14-001</org_study_id>
    <secondary_id>JapicCTI-152804</secondary_id>
    <nct_id>NCT02364947</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy, safety, and dose-response of nalmefene hydrochloride at 10 mg and 20 mg in
      patients with alcohol dependence will be evaluated in a multicenter, randomized,
      double-blind, placebo-controlled, 3-parallel-group comparative trial. The superiority of
      nalmefene hydrochloride at 20 mg to placebo will be verified in terms of reduction of
      alcohol consumption.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of Heavy Drinking Days (HDDs) from baseline</measure>
    <time_frame>Baseline (-2 weeks), 0, 1, 2, 4, 8, 12, 16, 20, and 24 weeks</time_frame>
    <description>The number of HDDs is defined as the number of days per month [days/month] with alcohol consumption of &gt; 60 g for males and &gt; 40 g for females</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Alcohol Consumption (TAC) from baseline</measure>
    <time_frame>Baseline (-2 weeks), 0, 1, 2, 4, 8, 12, 16, 20, and 24 weeks</time_frame>
    <description>TAC is defined as mean alcohol consumption per day [g/day] over a 1-month period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Nalmefene hydrochloride 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As-needed; tablets, orall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nalmefene hydrochloride 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As-needed; tablets, orall</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AS-needed; tablets, orall</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene hydrochloride</intervention_name>
    <description>As-needed; tablets, orally</description>
    <arm_group_label>Nalmefene hydrochloride 10 mg</arm_group_label>
    <arm_group_label>Nalmefene hydrochloride 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>As-needed; tablets, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese males and females aged 20 or above who have signed the informed consent form

          -  The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) and confirmed by
             Mini-international Neuropsychiatric Interview (M. I. N. I.)

        Exclusion Criteria:

          -  The patient with a current diagnosis or history of substance use disorders (except
             for alcohol, nicotine, and caffeine), according to DSM-IV-TR and confirmed by M. I.
             N. I.

          -  The patient has reported current use of, or has tested positive for, drugs of abuse
             (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hashimoto Jun-ichi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyugoku</name>
      <address>
        <city>Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>February 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nalmefene</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
